WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through China-Based Laboratory Services, U.S.-Based Laboratory Services, Clinical Research and Other CRO Services, CDMO Services, and Others segments. It offers laboratory services, such as synthetic chemistry, biology, medicinal chemistry, analytical chemistry, testing, drug metabolism and pharmacokinetics, toxicology, bioanalytical, and medical devices safety testing services, as well as manufacturing and testing for cell and gene therapies, and absorption, distribution, metabolism, and excretion services. The company also provides clinical research services, including clinical development and site management organization services; clinical development services comprising project planning, clinical operation, and monitoring and management of phase I-IV clinical trials, outcomes research, and medical device trials; embedded outsourcing; and clinical informatics services. In addition, it offers CDMO services; and administrative services, as well as sells raw and scrap materials. Further, the company engages in the laboratory-used biological assets cultivation business. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.